Australia Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore is a new market research publication announced by Reportstack.
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The UFE market has decreased in growth in part because of a reduction in active marketing. Moreover, UFE must compete with a wide array of procedures available to treat heavy bleeding due to uterine fibroids. These other treatments and procedures include hysterectomy, pharmacological alternatives, global endometrial ablation, endometrial resection and other minimally invasive surgical procedures.
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The UFE market has decreased in growth in part because of a reduction in active marketing. Moreover, UFE must compete with a wide array of procedures available to treat heavy bleeding due to uterine fibroids. These other treatments and procedures include hysterectomy, pharmacological alternatives, global endometrial ablation, endometrial resection and other minimally invasive surgical procedures.
Complete report available @ Australia Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore
The complete market is comprised of the microsphere and PVA particle sub-segments respectively. Despiute the overall decrease in the market, the microspheres segment is increasing significantly. The volume of microspheres required per procedure is much higher than the volume of PVA particles required per procedure; 3.5 microspheres are used for every 2 PVA particles required per procedure. The shift towards microspheres has diminished the severity of the drop in unit sales being caused by the declining procedure numbers.
Physicians may prefer the use of microspheres over PVA particles due to peer-reviewed journals that outline how microspheres result in reduced blood loss and higher efficacy in the reduction of fibroids compared to the alternative. PVA particles have been popular in the past due to their affordability and they were previously considered the standard of care.
Scope
2013-2023
2013-2023
Companies Mentioned
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
No comments:
Post a Comment